Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-10 (canceled)

Claim 11 (currently amended): A pharmaceutical composition comprising consisting of a solubilized therapeutic agent which is sparingly soluble in water and a carrier composition, said carrier composition consisting of:

- a) about 10-50% by weight, based on the carrier composition, of a sorbitan fatty acid ester co-surfactant which is substantially pure or which is in the form of a mixture of different sorbitan fatty acid esters, the co-surfactant having a hydrophilic-lipophilic balance of less than 10 (HLB value according to Griffin);
- b) about 5-40% by weight, based on the carrier composition, of a pharmaceutically acceptable oil which is substantially pure or which is in the form of a mixture, comprising a triglyceride as essential lipophilic component; and
- c) about 10-50% by weight, based on the carrier composition, of a nonionic surfactant which is substantially pure or which is in the form of a mixture, having an HLB value of more than 10;

and further optional pharmaceutically acceptable excipients, wherein the therapeutic agent is selected from the group consisting of rapamycin, tacrolimus, and mycophenolate-mofetil.

Claim 12 (previously presented): A pharmaceutical composition of claim 11, comprising about 1-30% by weight, based on the total weight of the carrier composition, of a sparingly soluble therapeutic agent having a solubility in pure water of less than 500 mg/1000 mL.

Claim 13 (canceled)

Claim 14 (previously presented): A pharmaceutical composition of claim 11, wherein component a) consists of a substantially pure sorbitan fatty ester, or of a mixture of sorbitan fatty esters, and the sorbitan skeleton is esterified with 1-3 acid radicals of saturated or unsaturated carboxylic acids having an even number of 8-20 carboxylic atoms.

Claim 15 (previously presented): A pharmaceutical composition of claim 11, wherein component a) contains as sorbitan fatty acid ester substantially pure sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monoleate, sorbitan sesquioleate, or sorbitan trioleate, or a mixture of these compounds.

Claim 16 (previously presented): A pharmaceutical composition of claim 11, wherein component b) contains as pharmaceutically acceptable oil ground nut oil, sesame oil, sunflower oil, olive oil, corn oil, soybean oil, castor oil, cottonseed oil, rapeseed oil, thistle oil, grapeseed oil, fish oil or neutral oil; and component c) contains a nonionic surfactant with a hydrophilic component consisting of 15-60 units of ethylene oxide.

Claim 17 (previously presented): A pharmaceutical composition comprising a solubilized therapeutic agent which is sparingly soluble in water; and a carrier composition, said carrier composition consisting of:

a) about 10-50% by weight, based on the carrier composition, of a co-surfactant having a hydrophilic-lipophilic balance of less than 10 (HLB value according to Griffin) which is a substantially pure sorbitan fatty ester, or of a mixture of sorbitan fatty esters, and the sorbitan skeleton is esterified with 1-3 acid radicals of saturated or unsaturated carboxylic acids having an even number of 8-20 carboxylic atoms;

- b) about 5-40% by weight, based on the carrier composition, of a pharmaceutically acceptable oil which is substantially pure or which is in the form of a mixture, comprising a triglyceride as essential lipophilic component; and
- c) about 10-50% by weight, based on the carrier composition, of a nonionic surfactant which is substantially pure or which is in the form of a mixture, having an HLB value of more than 10,

wherein said nonionic surfactant is an amphiphilic substance whose hydrophilic component consists of polyethylene oxide, and

wherein the therapeutic agent is selected from the group consisting of rapamycin, tacrolimus, and mycophenolate-mofetil.

Claim 18 (previously presented): The pharmaceutical composition of claim 17, wherein the polyethylene oxide component comprises 15 to 60 units of ethylene oxide.

Claim 19 (previously presented): A process for the preparation of a pharmaceutical composition of claim 11, which comprises mixing components a), b), and c) and further optional pharmaceutically acceptable water-soluble excipients in any order, dispersing in this mixture the therapeutic agent which is sparingly soluble in water and, if desired, processing the dispersion to a suitable dosage form for oral administration.

Claim 20 (previously presented): A process of claim 19, which comprises filling the dispersion into starch or hard or soft gelatin capsules.